Tag

Fda Approved

All articles tagged with #fda approved

health1 year ago

Revolutionary Cancer Treatments: Sound Waves, AI, and Precision Medicine

Histotripsy, a new FDA-approved cancer treatment, uses focused ultrasound waves to destroy tumors without harming surrounding tissue. This innovative method, which involves a water medium to focus soundwaves, offers advantages over traditional treatments like radiation. Chris Donaldson, a patient with ocular melanoma that spread to his liver, experienced successful results with histotripsy, leaving his liver cancer-free. The treatment, developed over 20 years, shows promise for other cancers and may enhance the body's defenses by leaving benign genetic material.

health1 year ago

Asheville Local Finishes Pioneering Cancer Vaccine Trial

Catie King, an Asheville native battling ovarian cancer, has completed her final injection in an FDA-approved cancer vaccine trial aimed at retraining the immune system to recognize and fight cancer. The trial, conducted by Elios Holdings, has shown promising results, with King reporting positive blood work and feeling great. The trial aims to enroll 60 patients, with King's participation drawing significant interest and applications. The vaccine is funded through donations and investors, providing hope to patients without cost. King will continue to be monitored, with data analysis expected in a year.

health1 year ago

FDA Approves New Alzheimer's Drug Kinsula, Offering Hope to Patients

Kisunla, a new FDA-approved drug, is being hailed as a "miracle" for its potential to treat Alzheimer's disease by improving memory and cognitive functions. Administered as a once-a-month injection, it offers hope to those in the early stages of dementia. The Baker Senior Center in Naples, where the drug is being celebrated, continues to support Alzheimer's patients with various programs, emphasizing hope and community.

health1 year ago

"Revolutionizing Depression Treatment: The Power of Transcranial Magnetic Stimulation"

Transcranial magnetic stimulation (TMS) is an FDA-approved therapy that has been around for more than a decade and is gaining attention as a potential treatment for those with treatment-resistant depression. The non-invasive treatment involves delivering pulses to the brain's neural circuitry, aiming to add energy to the brain and activate neurotransmitters. While time-consuming, with daily 30-minute sessions for six weeks, TMS has shown promising results, with nearly 70% of patients reporting a significant reduction in symptoms. This therapy is offering hope and changing lives for those struggling with depression.

health-and-medicine2 years ago

"Revolutionary RNA Switch Offers Precise Control Over Gene Therapy"

Researchers at Baylor College of Medicine have developed a novel gene regulation system that can turn genes on or off using FDA-approved doses of small molecules like tetracycline. This system, which operates by controlling the cleavage of a polyA signal in the RNA, promises to make gene therapy safer and more controllable, allowing for precise adjustments of therapeutic protein levels according to patient needs. The absence of foreign regulatory proteins reduces the risk of immune responses, making this a significant advancement in the field of gene therapy.

health2 years ago

"Local Pharmacies Prepare for RSV Outbreak with FDA-Approved Vaccine"

Local pharmacies are introducing a newly FDA-approved vaccine for respiratory syncytial virus (RSV) as an early seasonal outbreak is anticipated. The vaccine aims to provide protection against RSV, a common respiratory infection that can be severe in infants and older adults. With the approval of this vaccine, local pharmacies are taking proactive measures to prevent the spread of RSV and mitigate its impact on vulnerable populations.

business2 years ago

Sobi acquires CTI BioPharma for $1.7B, expands hematology portfolio.

Swedish Orphan Biovitrum (Sobi) has agreed to acquire CTI BioPharma for $1.7 billion in an all-cash transaction. The acquisition will diversify Sobi's portfolio of hematology medicines through CTI's lead product, Vonjo, which is FDA-approved for adult myelofibrosis patients with a platelet count below 50 x109/L. The transaction is expected to enhance Sobi's commercial footprint in the US and is fully funded through debt financing, up to half of which is expected to be refinanced through a rights issue. The transaction is expected to close in Q3 2023.